About US
Contact us
-
Particle Sciences Announces the Acquisition of Unique PEG-Based Polymer TechnologyParticle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its portfolio of drug delivery technologies through the acquisition of a versatile PEG-based technology. The technology2010/5/4
-
ViroPharma Begins Phase 2 Study Of Subcutaneous Delivery Of CinryzeViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase2010/4/30
-
Antares, Uman Pharma Partner For Drug Delivery Device Vibex MTXAntares Pharma, a provider of self-injection drug delivery technology and Uman Pharma, a manufacturer of injectable pharmaceutical products, have entered into an agreement for the injectable device Vi2010/4/30
-
BioProcess Technology Consultants’ Levine, Jones and Seymour to Speak at BIOHoward L. Levine, Ph.D., President, Susan Dana Jones, Ph.D., Vice President and Senior Consultant, and Patricia Seymour, Senior Consultant, of BioProcess Technology Consultants will be featured speake2010/4/29
-
Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format20100429.rar source: web of FDA2010/4/29
-
FDA Removes Last CFC Inhalers from the MarketLast week, after several years of debate and review, the US Food and Drug Administration called for metered-dose inhalers to be removed from the market. Seven such inhalers, largely used to treat asth2010/4/29
-
Pro-Tect Pharma Takes Over Nectid Drug Delivery PatentsPro-Tect Pharmaceuticals has acquired multiple patents and patents-pending from Nectid, that enable three revolutionary drug delivery technologies. Pro-Tect Pharmaceuticals said that the acquired pat2010/4/28
-
ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])ViroPharma Incorporated announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous adm2010/4/28
-
Synairgen plc Commences Phase II PoC Clinical Trial With Inhaled Interferon BetaSynairgen plc, a respiratory drug discovery and development company with a particular focus on viral defencse in asthma and chronic obstructive pulmonary disease (COPD), recently announced the2010/4/28
-
COVIDIEN LAUNCHES EXALGO™ EXTENDED-RELEASE TABLETSNew extended-release formulation available for around-the-clock pain management Covidien, a leading global provider of healthcare products, introduced EXALGO™ (hydromorphone HCI) Extended-Rele2010/4/27